Cost-Effectiveness Analysis of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable, Early-Stage Non–Small Cell Lung Cancer
- 1 December 2011
- journal article
- research article
- Published by Elsevier BV in International Journal of Radiation Oncology*Biology*Physics
- Vol. 81 (5), e767-e774
- https://doi.org/10.1016/j.ijrobp.2010.10.074
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJama-Journal Of The American Medical Association, 2010
- Comparative Effectiveness and Health Care Spending — Implications for ReformThe New England Journal of Medicine, 2010
- Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchusLung Cancer, 2009
- Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non–Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled TrialsJournal of Clinical Oncology, 2008
- Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study)The Lancet Oncology, 2008
- Survival of Patients with Stage I Lung Cancer Detected on CT ScreeningThe New England Journal of Medicine, 2006
- Racial Differences in the Treatment of Early-Stage Lung CancerThe New England Journal of Medicine, 1999
- Radiotherapy Alone for Medically Inoperable Stage I Non-Small–Cell Lung Cancer: The Duke ExperienceInternational Journal of Radiation Oncology*Biology*Physics, 1998
- A Note on QALYs, Time Tradeoff, and DiscountingMedical Decision Making, 1994
- Markov Models in Medical Decision MakingMedical Decision Making, 1993